Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

Clinical trial NCT07583810 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07583810
Sponsor: City of Hope Medical Center
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Marginal Zone Lymphoma Nodal Marginal Zone Lymphoma Splenic Marginal Zone Lymphoma Lymphoma Extranodal Marginal Zone Lymphoma

Start date: 2026-12-16
Primary completion: 2028-05-02
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.